Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan 17:13:574.
doi: 10.3389/fncel.2019.00574. eCollection 2019.

Altered Levels and Isoforms of Tau and Nuclear Membrane Invaginations in Huntington's Disease

Affiliations
Review

Altered Levels and Isoforms of Tau and Nuclear Membrane Invaginations in Huntington's Disease

Marta Fernández-Nogales et al. Front Cell Neurosci. .

Abstract

Since the early reports of neurofibrillary Tau pathology in brains of some Huntington's disease (HD) patients, mounting evidence of multiple alterations of Tau in HD brain tissue has emerged in recent years. Such Tau alterations range from increased total levels, imbalance of isoforms generated by alternative splicing (increased 4R-/3R-Tau ratio) or by post-translational modifications such as hyperphosphorylation or truncation. Besides, the detection in HD brains of a new Tau histopathological hallmark known as Tau nuclear rods (TNRs) or Tau-positive nuclear indentations (TNIs) led to propose HD as a secondary Tauopathy. After their discovery in HD brains, TNIs have also been reported in hippocampal neurons of early Braak stage AD cases and in frontal and temporal cortical neurons of FTD-MAPT cases due to the intronic IVS10+16 mutation in the Tau gene (MAPT) which results in an increased 4R-/3R-Tau ratio similar to that observed in HD. TNIs are likely pathogenic for contributing to the disturbed nucleocytoplasmic transport observed in HD. A key question is whether correction of any of the mentioned Tau alterations might have positive therapeutic implications for HD. The beneficial effect of decreasing Tau expression in HD mouse models clearly implicates Tau in HD pathogenesis. Such beneficial effect might be exerted by diminishing the excess total levels of Tau or specifically by diminishing the excess 4R-Tau, as well as any of their downstream effects. In any case, since gene silencing drugs are under development to attenuate both Huntingtin (HTT) expression for HD and MAPT expression for FTD-MAPT, it is conceivable that the combined therapy in HD patients might be more effective than HTT silencing alone.

Keywords: huntington’s disease; tau; tau nuclear indentation (TNI); tau nuclear rod (TNR); tauopathy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Presence of Tau nuclear indentations (TNIs) in Huntington’s disease (HD) brains. (A) Immunoelectron microscopy analysis of HD neurons with HT-7 positive nuclear indentations. Red arrows indicate the diaminobenzidine precipitate. (B) Immunohistochemistry with RD4 and Ht-7 antibodies in neurons of HD brain. (C) HT-7 immunofluorescence (green) with DAPI (blue) counterstaining in HD striatal neurons.

Similar articles

Cited by

References

    1. Andreadis A. (2005). Tau gene alternative splicing: expression patterns, regulation and modulation of function in normal brain and neurodegenerative diseases. Biochim. Biophys. Acta 1739, 91–103. 10.1016/j.bbadis.2004.08.010 - DOI - PubMed
    1. Andreadis A., Broderick J. A., Kosik K. S. (1995). Relative exon affinities and suboptimal splice site signals lead to non-equivalence of two cassette exons. Nucleic Acids Res. 23, 3585–3593. 10.1093/nar/23.17.3585 - DOI - PMC - PubMed
    1. Andreadis A., Brown W. M., Kosik K. S. (1992). Structure and novel exons of the human tau gene. Biochemistry 31, 10626–10633. 10.1021/bi00158a027 - DOI - PubMed
    1. Andrew S. E., Goldberg Y. P., Kremer B., Telenius H., Theilmann J., Adam S., et al. . (1993). The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington’s disease. Nat. Genet. 4, 398–403. 10.1038/ng0893-398 - DOI - PubMed
    1. Arendt T., Stieler J. T., Holzer M. (2016). Tau and tauopathies. Brain Res. Bull 126, 238–292. 10.1016/j.brainresbull.2016.08.018 - DOI - PubMed